Computed tomography follow-up after elective proximal aortic surgery: Less is more? - 23/05/22
, Anton Tomšič, MD, PhD a, Thomas J. van Brakel, MD, PhD a, Jaap F. Hamming, MD, PhD b, Arthur J.H.A. Scholte, MD, PhD c, Jesper Hjortnaes, MD, PhD a, Robert J.M. Klautz, MD, PhD aAbstract |
Study objective |
The added value of computed tomography (CT) follow-up after elective proximal aortic surgery is unclear. We evaluated the benefit of CT follow-up by assessing the incidence of aorta-related complications and reinterventions detected during routine CT follow-up.
Methods |
Data on 314 patients undergoing first time elective proximal aortic surgery between 2000 and 2015 were collected. The primary study end points were aorta-related complications and reinterventions, detected during routine CT follow-up. Secondary study endpoints included all aorta-related complications and reinterventions, irrespective of the mode of detection and survival.
Results |
Median CT follow-up time was 6.8 (IQR 4.1-9.8) years, during which a total of 1303 routine follow-up CT-scans (median 4, IQR 3-5) were performed. During CT follow-up, aorta-related complications were detected in 18 (5.7%) patients, of which 6 (1.6%) underwent reintervention. In total, 28 aorta-related complications were observed in 23 (7.3%) patients, of which 9 led to reintervention. In order to detect 1 aorta-related complication leading to reintervention, 218 routine follow-up CT-scans were required. The unadjusted and EuroSCORE II adjusted hazard ratios of not undergoing CT follow-up on mortality were 1.260 (95% CI 0.705-2.251) and 0.830 (95% CI 0.430-1.605), respectively.
Conclusions |
Following first time elective proximal aortic surgery, aorta-related complications are uncommon, are not always detected during CT follow-up and, if detected, often do not result in reintervention. Therefore, a more conservative CT follow-up protocol could be considered in selected patients to reduce lifetime radiation burden and health care costs.
Le texte complet de cet article est disponible en PDF.Plan
Vol 249
P. 66-75 - juillet 2022 Retour au numéro
Article précédent
- Double-blind, placebo-controlled evaluation of biorest liposomal alendronate in diabetic patients undergoing PCI: The BLADE-PCI trial
- Philippe Généreux, Gil Chernin, Abid R. Assali, Jan Z. Peruga, Simon D. Robinson, Erick Schampaert, Rodrigo Bagur, Samer Mansour, Josep Rodés-Cabau, Margaret McEntegart, Robert Gerber, Philippe L'Allier, Ranil de Silva, Benoit Daneault, Suneil K. Aggarwal, Vladimír Džavík, M. Ozgu Ozan, Ori Ben-Yehuda, Akiko Maehara, Gregg W. Stone, Michael Jonas
- Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial
- Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva, Thiago Ceccatto de Paula, Renata Junqueira Moll-Bernardes, Tiago Mendonça dos Santos, Lilian Mazza, Andre Feldman, Guilherme D`Andréa Saba Arruda, Denílson Campos de Albuquerque, Andrea Silvestre de Sousa, Olga Ferreira de Souza, C. Michael Gibson, Christopher B. Granger, John H. Alexander, Renato D. Lopes
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?